910. Treatment Strategies for Novel and Pandemic Influenza
Session: Symposium: Pandemic Influenza
Friday, October 5, 2018: 9:10 AM
Room: S 305-314
Frederick Hayden, MD, Medicine, University of Virginia School of Medicine, Charlottesville, VA


Disclosures:

F. Hayden, Shionogi: Consultant , Charitable donation to Robert Ford Haitian Orphanage and School; travel support to speak at 6th ESWI Conference, Riga, Latvia 2017 . Seqirus: Consultant , Charitable donation to Robert Ford Haitian Orphanage and School . PrEP Biopharm: Consultant , Charitable donation to Robert Ford Haitian Orphanage and School . Genentech/Roche: Consultant , Not compensated . GSK: Consultant , Not compensated . Fujifilm/Toyama/Medivector: Consultant , Not compensated . Vir: Consultant , Not compensated . Visterra: Consultant , Not compensated . Janssen: Consultant , Not compensated . CoCrystal: Consultant , Not compensated . Farmak: Consultant , Not compensated . GSK: DSMB Member , Fees paid to University of Virginia . Celltrion: Chair, DSMB , Fees paid to University of Virginia . Vaccitech: DSMB member , Fees paid to University of Virginia . MedImmune: Consultant , Not compensated . resTORbio: Consultant , Not compensated . Regeneron: Consultant , Not compensated .

See more of: Pandemic Influenza
See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.